Biogen Inc. (BIIB) Stock | Share Price | US09062X1037 | News

BIIB · Health Care · United States United States

Biogen Inc. (BIIB) is a company in the Health Care sector, based in United States. The stock is held in 23 ETFs we track – with its largest weight of 0.50 % in XUHC (msci-usa-health-care). That means you can hold Biogen indirectly and diversified through an ETF savings plan.

Very high ETF coverage: 23 of the 95 ETFs we cover hold Biogen, spread across 11 indices. That puts the stock in more ETFs than 91.5 % of the 4,362 stocks we cover.

Held in23 ETFs
Highest weight0.50 %
Indices11
SectorHealth Care
CountryUnited States
ISINUS09062X1037
WKN789617

Data note 1

Price chart

Data note 2

Performance

Performance
Year to date+24.3 %1 year+61.7 %
1 month+10.5 %3 months+12.2 %
Calendar year 2025+15.1 %
Calendar year 2026+25.6 %
52W

Data note 3

Risk metrics

Max drawdown-45.0 %
Volatility p.a.32.3 %
Best year2026: +25.6 %
Worst year2025: +15.1 %

Data note 4

Correlated with

The strongest co-movers on top, the most inverse below. Low or negative values improve portfolio diversification.

Data note 5

Key financials

Latest reported fiscal year (FY2025, period end 2025-12-31) as filed with the SEC.

Revenue9.9 bn $
Net income1.3 bn $
Diluted EPS8.79 $
Net margin13.1 %
Return on equity8.7 %
Equity ratio50.3 %
Revenue growth+2.2 %
Revenue and profit by fiscal year
Fiscal yearRevenueNet incomeMargin
FY20239.81.211.8 %
FY20249.71.616.9 %
FY20259.91.313.1 %

Data note 6

Figures in USD bn. Source: SEC EDGAR (XBRL annual filings, public domain). US-listed SEC filers only.

Held in these ETFs

Data note 7

Want to know how much Biogen Inc. overlaps with the rest of your portfolio? Use the Portfolio X-Ray or the ETF overlap check.

Stocks with similar ETF exposure

Names that reach a portfolio through largely the same funds as Biogen — the figure counts the ETFs holding both.

Data note 8

In the Alysly network

How Biogen Inc. connects to ETFs, indices and neighbouring names — every link is a measured relation, not a recommendation.

View the full network

Latest Investment Intelligence News: Stocks